Skip to main content

Table 2 Demographics and transplant details

From: Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

Characteristic MRD negative MRD positive P
N 1816 964  
Median follow-up, (months, IQR) 39.70 (12.89–84.20) 44.56 (16.07–82.07) 0.410
Median age (years, range, IQR) 36 (18–70, 26–46) 38 (18–72, 28–48) < 0.001
Median time dg to HCT (months, range, IQR) 5.7 (1.9–130, 4.6–8) 5.6 (2.3–123, 4.5–7.7) 0.182
Median year of HCT (range) 2012 (2000–2017) 2012 (2000–2017) 0.687
Median donor age (years, range, IQR, missing) 34 (4–73, 26–44, 643) 35 (10–72, 27–44, 293) 0.080
In vivo TCD    0.221
 No in vivo TCD 1099 (62%) 565 (60%)  
 In vivo TCD 670 (38%) 381 (40%)  
 Data missing 47 18  
Remission status at HCT    0.518
 CR1 1580 (87%) 847 (88%)  
 CR2 236 (13%) 117 (12%)  
ALL subtype    < 0.001
 B-ALL Ph-negative 479 (26%) 181 (19%)  
 B-ALL Ph-positive 882 (49%) 639 (66%)  
 T-ALL 455 (25%) 144 (15%)  
Karnofsky score at HCT    0.203
 < 80% 60 (4%) 41 (5%)  
 > =80% 1639 (96%) 861 (95%)  
 Data missing 117 62  
Engraftment    0.459
 Engrafted 1732 (98%) 925 (99%)  
 Graft failure 29 (1.7%) 12 (1.3%)  
 Data missing 55 27  
Source of stem cells    0.008
 Bone marrow 409 (23%) 261 (27%)  
 Blood 1407 (78%) 703 (73%)  
Donor type    0.268
 Matched sibling 1041 (57%) 531 (55%)  
 Unrelated 10/10 match 575 (32%) 308 (32%)  
 Unrelated 9/10 match 200 (11%) 125 (13%)  
Conditioning    0.628
 Chemotherapy-based 435 (24%) 223 (23%)  
 TBI containing 1381 (76%) 741 (77%)  
Patient sex    0.285
 Male 1097 (60%) 603 (63%)  
 Female 717 (40%) 361 (37%)  
 Data missing 2 0  
Donor sex    0.267
 Male 1107 (62%) 606 (64%)  
 Female 693 (39%) 346 (36%)  
 Data missing 16 12  
Donor–recipient sex mismatch    0.411
 Female to male 391 (22%) 195 (20%)  
 Other 1409 (78%) 762 (80%)  
 Data missing 16 7  
Patient CMV serology    0.950
 Negative 637 (37%) 342 (37%)  
 Positive 1090 (63%) 582 (63%)  
 Data missing 89 40  
Donor CMV serology    0.690
 Negative 790 (46%) 414 (45%)  
 Positive 927 (54%) 502 (55%)  
 Data missing 99 48  
CMV donor/recipient    0.975
 Negative to negative 450 (27%) 239 (27%)  
 Positive to negative 176 (10%) 99 (11%)  
 Negative to positive 317 (19%) 166 (18%)  
 Positive to positive 743 (44%) 398 (44%)  
 Data missing 130 62  
HCT-comorbidity index    0.128
 1 or 2 529 (85%) 271 (81%)  
 > =3 92 (15%) 62 (19%)  
 Data missing 1195 631  
GVHD prevention    0.054
 Cyclosporin 124 (7%) 60 (6%)  
 Cyclosporin and MTX 1247 (70%) 702 (74%)  
 Cyclosporin and MMF ± MTX 181 (10%) 101 (11%)  
 Tacrolimus ± other 115 (7%) 41 (4%)  
 Other 103 (6%) 41 (4%)  
 Data missing 46 19  
Acute GVHD    0.139
 Grade 0–I 1156 (67%) 594 (64%)  
 Grade II–IV 564 (33%) 329 (36%)  
 Data missing 96 41  
Donor lymphocyte infusion    < 0.001
 None received 1681 (93%) 846 (88%)  
 Pre-emptive 36 (2%) 48 (5%)  
 After relapse 97 (5%) 67 (7%)  
 Data missing 2 3  
  1. Abbreviations: CR complete remission, CMV cytomegalovirus, GVHD graft-versus-host disease, HCT hematopoietic cell transplantation, IQR interquartile range, dg diagnosis, MMF mycophenolate mofetil, MTX methotrexate; MRD measurable residual disease, Ph Philadelphia chromosome/BCR-ABL gene rearrangement, TCD T cell depletion